{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:31:45Z","timestamp":1694633505741},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.jgyn.2008.07.003","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T09:02:09Z","timestamp":1219827729000},"page":"748-752","source":"Crossref","is-referenced-by-count":2,"title":["Place de la vaccination antipapillomavirus apr\u00e8s 25 ans"],"prefix":"10.1016","volume":"37","author":[{"given":"P.","family":"Simon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Poppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgyn.2008.07.003_bib1","doi-asserted-by":"crossref","unstructured":"ESGO Statement on Cervical Cancer Vaccination Int J Gynecol Cancer 2007; 17:1183\u201385.","DOI":"10.1111\/j.1525-1438.2007.01129.x"},{"key":"10.1016\/j.jgyn.2008.07.003_bib2","unstructured":"Flemish Cancer Registry Network (E. Van Eycken et al.: Cancer Incidence and survival in Flanders, 2006, VLK, Brussels)."},{"issue":"9580","key":"10.1016\/j.jgyn.2008.07.003_bib3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"370","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2008.07.003_bib4","doi-asserted-by":"crossref","unstructured":"The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356;19 1915\u201327.","DOI":"10.1056\/NEJMoa061741"},{"key":"10.1016\/j.jgyn.2008.07.003_bib5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jgyn.2008.07.003_bib6","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3201\/eid1111.050575","article-title":"Cervical human papillomavirus screening among older women","volume":"11","author":"Grainge","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgyn.2008.07.003_bib7","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/aje\/kwj077","article-title":"Modelling the sexual transmissibility of human papillomavirus infection using stochatic computer simulation and empirical data from a cohort study of young women in Montreal Canada","volume":"163","author":"Burchell","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jgyn.2008.07.003_bib8","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"JID"},{"key":"10.1016\/j.jgyn.2008.07.003_bib9","doi-asserted-by":"crossref","unstructured":"Coup\u00e9 VMH, Berkhof J, Bulkmans NWJ Snijders PJ, Meijer CJ. Age dependent prevalence of 14 high risk HPV types in the Netherlands: implications for prophylactic vaccinationand screening. B J Cancer 2008, 1\u20136 online publication www.bjcancer.com.","DOI":"10.1038\/sj.bjc.6604162"},{"key":"10.1016\/j.jgyn.2008.07.003_bib10","first-page":"238","article-title":"Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26","volume":"188","author":"Skinner","year":"2008","journal-title":"MJA"},{"key":"10.1016\/j.jgyn.2008.07.003_bib11","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1158\/0008-5472.CAN-06-1057","article-title":"The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10 year period","volume":"66","author":"Kjaer","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jgyn.2008.07.003_bib12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type6specific HPV testing in preclinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgyn.2008.07.003_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/CDLI.4.2.122-126.1997","article-title":"Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women","volume":"4","author":"Viscidi","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.jgyn.2008.07.003_bib14","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18 and 6 capsid antibody response following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgyn.2008.07.003_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1055-9965.EPI-03-0166","article-title":"Seroractivity to human papillomavirus (HPV) type 16,18or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica","volume":"13","author":"Viscidi","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jgyn.2008.07.003_bib16","doi-asserted-by":"crossref","unstructured":"Schwarz TF. Human papillomavirus (HPV) 16\/18 L1 ASO4 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 24 months after vaccination in women up to age 55 years. EUROGIN 2007.","DOI":"10.1200\/jco.2007.25.18_suppl.3007"},{"key":"10.1016\/j.jgyn.2008.07.003_bib17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus 16 and 18: follow up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2008.07.003_bib18","unstructured":"Schwarz T; Correlation between serum & cervical mucose antibody levels EUROGIN 2007."},{"key":"10.1016\/j.jgyn.2008.07.003_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/jco.2006.24.18_suppl.1008","article-title":"An AS04-containing human papillomavirus 16\/18 vaccine for prevention of cervical cancer is immunogenic and well tolerated in women 15-55 years old","volume":"24","author":"Schwarz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgyn.2008.07.003_bib20","unstructured":"Luna J, Saah A, Hood S, Barr E. Safety, efficacy and immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. 24th International Papillomavirus Congress Bejing China 2007"},{"key":"10.1016\/j.jgyn.2008.07.003_bib21","doi-asserted-by":"crossref","unstructured":"Skinner R, Verheijen R, Martens M, Salieron J, Kittisak W et al. Estimating prior HPV 16\/18 exposure by age group of women enrolled in phase III clinical trials of GSK4s HPV vaccine. EUROGIN 2007.","DOI":"10.1071\/SHv4n4Ab55"},{"key":"10.1016\/j.jgyn.2008.07.003_bib22","unstructured":"Cruickshank M, Teixeira J, Gall S, Raymundo R, Garland S et al. Efficacy and safety of GSK4s vaccine in women initially seropositive or seronegative for HPV-16\/18 in a phase III trial. EUROGIN 2007."},{"key":"10.1016\/j.jgyn.2008.07.003_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 viruslike particle vaccine among young women with pre-existing infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"}],"container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231508002317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0368231508002317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T14:26:09Z","timestamp":1631715969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0368231508002317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0368231508002317"],"URL":"https:\/\/doi.org\/10.1016\/j.jgyn.2008.07.003","relation":{},"ISSN":["0368-2315"],"issn-type":[{"value":"0368-2315","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}